Subclinical hypothyroidism (SCH) is a common condition among older men and women. Although by definition SCH comprises biochemically mild thyroid hormone deficiency without overt symptoms, it is a possible contributor to multiple problems in older age. Thyroid hormone has effects on numerous physiological systems, including the vascular tree, heart, skeletal muscle and brain. Therefore, thyroxine substitution to overcome thyroid hormone deficiency has the potential to give multisystem benefits to older people with SCH. Small studies have reported reduced atherosclerosis and improved heart function with thyroxine replacement, but no large clinical trials have been performed. Therefore the available evidence is limited, leading to major variations in guidelines and clinical practice, with uncertainty regarding the indications for screening and treatment. The investigators propose a multicentre randomised placebo controlled trial to assess the impact of thyroxine replacement in a minimum of 540 older adults (maximum 750) with persisting SCH (excluding those in whom it is a temporary phenomenon who are unlikely to benefit). The investigators will include older men and women with a wide age range and of varying health status. Outcomes include health related quality of life, muscle strength, executive cognitive function and cardiovascular events, with a minimum of 1 year of follow up. Blood and urine samples will be stored in a biobank, to allow future research on causes of ill health in older people with SCH. The investigators have the support of patient advocacy groups and a consortium with the wide range of expertise and experience required to conduct large scale multicentre clinical trials. The proposal explores the multisystem and quality of life benefits to older people of a tailored approach to management of SCH. This clinical trial should definitively clarify whether thyroxine treatment for SCH provides benefits that are relevant for patients. This trial will provide strong evidence with the potential to improve clinical practice, reduce health care costs and promote healthy ageing of older adults.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
737
The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde
Glasgow, United Kingdom
Thyroid-specific quality of life - Hypothyroid symptoms and Fatigue symptoms (co-primary outcomes)
Change in Hypothyroid Symptoms and Fatigue scores (measured using the Thyroid-specific quality of life Patient Reported Outcome questionnaire - ThyPRO; Hypothyroid symptoms and Fatigue domains).
Time frame: Measured at baseline and 12 months
Health-related quality of life
The EuroQol5D
Time frame: measured at baseline; 3 month; 12 month and final follow up (expected mean follow-up of 18 months).
Handgrip strength
Handgrip strength measured using the Jadaar hand dynamometer.
Time frame: Measured at baseline; 12 months and final follow up (expected mean follow-up of 18 months).
Executive cognitive function
Letter Digit Coding Test \[LDCT).
Time frame: Measured at baseline and final follow-up (expected mean follow-up of 18 months).
Total mortality
Total mortality
Time frame: Up to final follow up (expected mean follow-up of 18 months).
Basic Activities of Daily Living
Basic Activities of Daily Living (ADL) measured using the 20-point Barthel Index \[BI\].
Time frame: Measured at baseline and final follow-up (expected mean follow-up of 18 months).
Extended activities of daily living
Extended activities of daily living measured using the older American resources and services \[OARS\]) questionnaire
Time frame: Measured at baseline and final follow-up (expected mean follow-up of 18 months).
Haemoglobin
Change in haemoglobin, measured on a full blood count
Time frame: Measured at baseline and 1 year
Fatal and non-fatal cardiovascular events
This will include fatal and non fatal acute myocardial infarction and stroke; amputations for peripheral vascular disease; revascularisations for atherosclerotic vascular disease, including for acute coronary syndrome; heart failure hospitalisations.
Time frame: Expected mean follow-up of 18 months.
Generic thyroid specific quality of life
Thyroid-related quality of life Patient-Reported Outcome measure (ThyPRO) 39
Time frame: Final follow-up
Thyroid-specific quality of life - Hypothyroid symptoms
Change in hypothyroid symptom burden (measured using the Thyroid-specific quality of life Patient Reported Outcome questionnaire - ThyPRO; Hypothyroid symptoms domain).
Time frame: Measured at 6-8 weeks and at final review
Thyroid specific quality of life - Fatigue symptoms
Change in fatigue (measured using the Thyroid-specific quality of life Patient Reported Outcome questionnaire - ThyPRO; Fatigue and vitality domain).
Time frame: Measured at 6-8 weeks and at final review
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.